In-Bore Transrectal MRI-Guided Biopsy With Robotic Assistance in the Diagnosis of Prostate Cancer: An Analysis of 57 Patients

被引:14
|
作者
Barral, Matthias [1 ]
Lefevre, Arnaud [2 ]
Camparo, Philippe [3 ]
Hoogenboom, Martijn [4 ]
Pierre, Thibaut [1 ]
Soyer, Philippe [1 ,5 ]
Cornud, Francois [1 ,2 ]
机构
[1] Hop Cochin, AP HP, Dept Radiol, 27 Rue Faubourg St Jacques, F-75014 Paris, France
[2] Clin Alma, Paris, France
[3] Ctr Pathol, Amiens, France
[4] Soteria Med, Arnhem, Netherlands
[5] Paris Descartes Univ, Paris, France
关键词
in-bore MRI guidance; prostatic cancer; robotic assistance; transrectal prostate biopsy; DATA SYSTEM; ULTRASOUND; FUSION; REGISTRATION; ACCURACY; FEASIBILITY; MANIPULATOR; VISIBILITY; STANDARD; LESIONS;
D O I
10.2214/AJR.19.21145
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The objective of our study was to analyze the feasibility and potential role of robotic-assisted transrectal MRI-guided biopsy for the diagnosis of prostate cancer. MATERIALS AND METHODS. A total of 57 patients (mean age, 67 +/- 6 [SD] years; age range, 57-83 years; mean prostate-specific antigen level, 10.7 +/- 6.1 ng/mL) with a single prostatic lesion visible on biparametric MRI (T2-weighted and DW images) underwent robotic-assisted MRI-guided transrectal biopsy. The procedure was analyzed in terms of technical success, defined by an accurate alignment of the needle guide with the lesion; occupation time of the MRI room; number of cores; cancer detection rate (CDR); and complications. RESULTS. The biparametric MRI score was 3, 4, and 5 in 11 (19%), 30 (53%), and 16 (28%) of the 57 patients, respectively. Twenty-three lesions (23/57, 40%) originated in the peripheral zone and 34 (34/57, 60%) in the transition zone. Software-based adjustments of the robot allowed the needle guide to be aligned with the target in all lesions. The number of cores was one, two, three, and four in one (2%), 36 (63%), 18 (32%), and three (5%) patients, respectively. Obtaining more than two cores had no incremental value in determining the Gleason score or the maximum cancer core length (MCCL). The overall CDR for any cancer was 67% (38/57). It was 95% (36/38) for tumors with Gleason grade of more than 3 or MCCL greater than 3 mm and 53% (20/38) for tumors with Gleason score greater than 6. No complications were observed. The median occupation time of the MRI room was 37.8 +/- 9.7 minutes (range, 32-74 minutes). CONCLUSION. Robotic-assisted MRI-guided biopsy yields 100% technical success rate with a short MRI room occupation time and high CDRs using one or two cores.
引用
收藏
页码:W171 / W179
页数:9
相关论文
共 50 条
  • [21] In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer
    Felker, Ely R.
    Lee-Felker, Stephanie A.
    Feller, John
    Margolis, Daniel J.
    Lu, David S.
    Princenthal, Robert
    May, Stuart
    Cohen, Martin
    Huang, Jiaoti
    Yoshida, Jeffrey
    Greenwood, Bernadette
    Kim, Hyun J.
    Raman, Steven S.
    ABDOMINAL RADIOLOGY, 2016, 41 (05) : 954 - 962
  • [22] In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer
    Ely R. Felker
    Stephanie A. Lee-Felker
    John Feller
    Daniel J. Margolis
    David S. Lu
    Robert Princenthal
    Stuart May
    Martin Cohen
    Jiaoti Huang
    Jeffrey Yoshida
    Bernadette Greenwood
    Hyun J. Kim
    Steven S. Raman
    Abdominal Radiology, 2016, 41 : 954 - 962
  • [23] MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature
    Pokorny, Morgan
    Kua, Boon
    Esler, Rachel
    Yaxley, John
    Samaratunga, Hemamali
    Dunglison, Nigel
    Gianduzzo, Troy
    Coughlin, Geoff
    Holt, Ross
    Laing, Barbara
    Ault, Darren
    Brown, Nicholas
    Parkinson, Rob
    Thompson, Les
    WORLD JOURNAL OF UROLOGY, 2019, 37 (07) : 1263 - 1279
  • [24] MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature
    Morgan Pokorny
    Boon Kua
    Rachel Esler
    John Yaxley
    Hemamali Samaratunga
    Nigel Dunglison
    Troy Gianduzzo
    Geoff Coughlin
    Ross Holt
    Barbara Laing
    Darren Ault
    Nicholas Brown
    Rob Parkinson
    Les Thompson
    World Journal of Urology, 2019, 37 : 1263 - 1279
  • [25] Direct MRI-guided In-Bore Targeted Biopsy of the Prostate: A Step-by-Step How To and Lessons Learned
    Recchimuzzi, Debora Z.
    de Leon, Alberto Diaz
    Pedrosa, Ivan
    Travalini, Debbie
    Latin, Heather
    Goldberg, Kenneth
    Meng, Xiaosong
    Begovic, Jovan
    Rayan, Jesse
    Roehrborn, Claus G.
    Rofsky, Neil M.
    Costa, Daniel N.
    RADIOGRAPHICS, 2024, 44 (02)
  • [26] MRI-GUIDED TRANSRECTAL BIOPSY OF THE PROSTATE FOR PATIENTS WITH PREVIOUS NEGATIVE TRUS BIOPSY IN 69 PATIENTS
    Schilling, D.
    Lichy, M. P.
    Pelzer, A.
    Hennenlotter, J.
    Anastasiadis, A. G.
    Renninger, M.
    Kruck, S.
    Schlemmer, H. P.
    Stenzl, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 330 - 330
  • [27] Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies
    Schouten, Martijn G.
    Bomers, Joyce G. R.
    Yakar, Derya
    Huisman, Henkjan
    Rothgang, Eva
    Bosboom, Dennis
    Scheenen, Tom W. J.
    Misra, Sarthak
    Futterer, Jurgen J.
    EUROPEAN RADIOLOGY, 2012, 22 (02) : 476 - 483
  • [28] Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies
    Martijn G. Schouten
    Joyce G. R. Bomers
    Derya Yakar
    Henkjan Huisman
    Eva Rothgang
    Dennis Bosboom
    Tom W. J. Scheenen
    Sarthak Misra
    Jurgen J. Fütterer
    European Radiology, 2012, 22 : 476 - 483
  • [29] MRI-guided Prostate Biopsy: Transrectal versus transperineal Approach
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2025, 56 (02)
  • [30] MRI-guided biopsy for prostate cancer diagnosis: Less is more
    Hagens, M. J.
    Noordzij, M. A.
    Schoots, I. G.
    Van Leeuwen, P. J.
    Van der Poel, H. G.
    Rynja, S. P.
    EUROPEAN UROLOGY, 2022, 81 : S696 - S697